Skinbiotherapeutics Price: SBTX Reaches a Peak, May Face a Retrace at 25 Points

PUBLISHED: 15 Mar 2025 @ 11:10 | Comments (0) | More info about Azeez Mustapha

Looking at the steady northward pathway of the system that bulls have been pushing in the exchange lines of Skinbiotherapeutics Plc (LSE:SBTX), it is likely that the stock market may face a retrace at 25 points soon, given that it reaches a peak.

The price movements, reflected in a series of bullish candlesticks, suggest that buyers have largely exhausted their upward momentum, struggling to maintain positions above the moving average indicators. This could signal a potential deviation from established technical principles, indicating a higher risk of price reversal or consolidation.

Resistance Levels: 27.5, 30, 32.5
Support Levels: 20, 17.5, 15

Judging by the postures of the indicators, will the SBTX Plc stock see logical longing entries above the EMAs subsequently?

As it stands, if the bears’ responses do not produce a series of selling candlesticks around the current trade level, the subsequent price actions could trigger a consolidation phase, especially if Skinbiotherapeutics Plc shares reach a peak and are likely to retrace around the 25-point level.

The trend line of the 15-day EMA is positioned above the 50-day EMA, both trending northward across the 20 level with close proximity. As of the latest data, the stochastic oscillators have moved northward into the overbought region, signaling that buying momentum has reached a critical juncture—either poised for a brief consolidation or facing a potential reversal.

Learn from market wizards: Books to take your trading to the next

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

Follow @ItuGlobal

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.